

Improving Colorectal Cancer Screening Rates in North Dakota



It's A Matter of Choice

There are many screening tests for CRC! Which is the best?

Colonoscopy FIT Cologuard



The test that the patient completes!





Improving Colorectal Cancer Screening Rates in North Dakota

How do you think offering choice improves CRC screening rates?

Dan Beach, FNP-C South Central Health

Clinic Story

CRC Test Choice: Calling Patients and Offering Stool Test Kits Raise Colorectal Cancer Screening Use in South Dakota

The Sanford Watertown Clinic tried but could not raise its colorectal cancer screening use. Patients said they didn't get screened because of the cost, they didn't like the preparation needed for a colonoscopy, they were afraid of a colonoscopy, or they couldn't take time off from work.

Care managers at the clinic made a list of patients who needed to be screened. They called these patients to talk about why they should be screened and the different tests available to them.

As a result, 21 patients scheduled a colonoscopy. The care managers mailed 100 stool test kits to patients not getting a colonoscopy; more than half of the tests were completed and returned. Three completed test kits had positive results, and all three people then had a colonoscopy. The clinic's screening use went up from 66% to almost 75% within a few months.

https://www.cdc.gov/cancer/crccp/success/test-choice.htm

Considerations



Screening Options	Pros	Cons
FIT or iFOBT (Immunochemical) - Annual	 Sample collection at home No colon prep Only one sample (1 BM) No sedation Overall diagnostic accuracy of 95% Lowest cost (\$75-\$125) 	 Fails to detect polyps Additional tests needed if positive Lowest risk of false-positive result
Stool DNA (Cologuard) - q 3yrs	 Sample collection at home No colon prep Requires collecting an entire BM (vs a sample) No sedation Cost of \$500 (q3 yrs) 	 Less sensitive than colonoscopy at detecting precancerous polyps Additional tests needed if positive False-positive result
Colonoscopy - 30-60 min,q-10yrs	 One of the most sensitive tests currently available Doctor can view entire colon and rectum Abnormal tissue, such as polyps, and tissue samples (biopsies) can be removed through the scope during exam 	 May not detect all small polyps and cancers Bowel prep required Sedation required Need a driver Rare complications: bleeding from site of polyp or biopsy; tear in colon or rectum wall Cramping/bloating may occur afterward



"We have a menu of screening options. There is no reason to prefer one test over another."

- Dr. Uri Ladabaum, MD

Shared decision-making tools:

Screening for colorectal cancer (CRC) on time matters'

How CRC develops'

You have choices when it comes to CRC screening^{1,6-8} The best test is the one that gets done

	Colonoscopy (desual maxm)	Multitarget stool DNA test*	FIT/FOBT* theat energy theory	
Q How does it w	ork? Uses a scope to look for and remove abnormal growths in the colon/rectum	Finds abnormal DNA and blood in the stool sample	Detects blood in the stool sample	
Who is it for?	Adults at high or average risk	Adults 45+ at average risk	Adults at average risk	
How often?	Every 10 years!	Every 3 years*	Once a year	
Noninvasive?	No	Yes, used at home	Yes, used at home	
Prep required	Yes, full bowel prep including fasting and laxatives	Nα	No/Yes*	
🕑 Time it takes?	1-2 days for bowel prep and procedure	Just the time it takes to collect a sample	Just the time it takes to collect a sample	
(\$) Covered?*	Covered by most insurers	Covered by most insurers	Covered by most insurers	
After a positive result?	Polyps removed and examined (biopsy)	Follow-up colonoscopy	Follow-up colonoscopy	
*All positive results on non- screening lests should be t with timely colonoscopy.	International of the second se	*FIT does not require changes to diet or medication, FORT requires changes to thet or medication.	Nnaurance coverage can vary: only your insurer can confirm hew CRC screening would be covered under your insurance policy.	
Regular screen	ing has the potential to save lives	. But no one is saved by not	screening. ⁷	
Choose an option with your prescrib		Multitarget stool O F	FIT/FOBT ONone	

References

- American Cancer Society. Colorectal cancer facts & figures 2020-2022. Attanta: American Cancer Society; 2020.
- National Cancer Institute. SEER cancer stat facts: colorectal cancer. https://seer.cancer.gov/statfacts/html/colorect.html.Accessed December 3, 2020.
 Itskowstr.SH. Incremental advances in excremental cancer detection tests. J Nat/ Cancer
- Inst. 2009;101(18):1225-1227. 4. Siegel RL, Miller KD, Jemal A, Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
- Sieger HL, Miller KD, Jemai A, Cancer statistics, 2020. CA Cancer J Can. 2020;r0(1):r-30.
 Patel SG. Ahnan DJ. Familial colon cancer syndromes: an update of a rapidly evolving field.
- Curr Gastroenterol App. 2012;14(5):428-438. 6. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk
- adults: 2018 guidelines update from the American Center Society, CA Center J Clin. 2018;68(4):250-281.
- 7: US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315(23)2564-2575.
 8: American Cancer Society. Insurance coverage for colorectal cancer screening. https:// www.cancer.org/cancer/color-metal-cancer/detaction-diagnosis-staging/screeningcoverage-two.html. Accessed December 3, 2020.



EXACT SCHACES CORPORATION 411 Charmany Derive, Madixon, WI 53719 www.ExactSciences.com | www.ExactLabs.com | 1-044-870-8870 02920 Exact Sciences Corporation. All rights reserved. US:06:2861-20-corenter 2020

Population Age-Eligible for Colorectal Cancer Screening, by Census Tract, and Location of Facilities for Colonoscopy, North Dakota, 2016



Source: 2011–2015 American Community Survey 5-year estimates (1)

Vu MH, Tran JL. Visualizing colonoscopy capacity for public health use. Prev Chronic Dis 2018;15:170421.

Making the Best Use of Scarce Resources:

Screening colonoscopy vs. FIT

Represents 20 patients



Stool tests appropriate only for average risk clients

All positive tests must be followed up with colonoscopy

Slide courtesy of Dr. G.Coronado

FIT Tests are not created equal

FIT BRAND NAME	MANUFACTURER	SENSITIVITY FOR CANCER ^{†,‡}	SPECIFICITY FOR CANCER ^{†,‡}	NUMBER OF STOOL SAMPLES
Automated (non-CLIA waived) FITs			W 111 111	
OC Auto-FIT*	Polymedco	65%-92.3% ^{3,4}	87.2%-95.5% ^{3,4}	1
CLIA-waived FITs				
OC-Light iFOB Test (also called OC Light S FIT)	Polymedco	78.6%-97.0% ^{3,4}	88.0%-92.8% ^{3,4}	1
QuickVue iFOB	Quidel	91.9% ⁵	74.9% ⁵	1
Hemosure One-Step iFOB Test	Hemosure, Inc.	54.5% ³	90.5%3	1 or 2
InSure FIT	Clinical Genomics	75.0%	96.6%	2
Hemoccult-ICT	Beckman Coulter	23.2%-81.8% ³	95.8%-96.9% ³	2 or 3

WHAT???

http://nccrt.org/wp-content/uploads/dlm_uploads/IssueBrief_FOBT_CliniciansRef-09282019

Peer Sharing

- Are your providers hesitant to use stool tests? Why/How can we provide the information they need to reconsider?
- What CRC Screening options are currently offered to your patients? How was it decided?
- When patients refuse CRC screening, are barriers to the tests discussed? Options offered?

Resources for the Journey Ahead

Resources

- <u>Effectiveness of Interventions to</u> <u>Increase Colorectal Cancer</u> <u>Screening Among American Indians</u> <u>and Alaska Natives</u>
- ACS: FluFIT Implementation Guide
- <u>Colorectal Cancer Screening: Which</u> <u>test is right for you?</u> (Decision aid)
- FIT/iFOBT Clinician Reference

Next Steps

- TA Calls
- Evaluation (required for CEUs):

Next collaborative call: 1/10/2023, 1:00 pm CT | Topic: Crappy Communication

ScreeND Contact Information

Nikki Medalen, MS, BSN Quality Improvement Specialist <u>nmedalen@qualityhealthnd.org</u> | 701-989-6236

Jonathan Gardner

Network Administrator/Data Analyst jgardner@qualityhealthnd.org | 701-989-6237

